Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?   

Do any studies support this rationale? Does the presence of a somatic vs germline BRCA mutation impact your decision?

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Onc San Antonio
Thank you, Dr. @Banu Arun.  If I can ask her...
Sign in or Register to read more